(Q39516263)

12 September 2017

title

The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells (English)

1 reference

12 September 2017

1 reference

Ansgar Brüning

1

1 reference

12 September 2017

Petra Burger

series ordinal

2

1 reference

12 September 2017

Andrea Gingelmaier

series ordinal

3

1 reference

12 September 2017

Ioannis Mylonas

series ordinal

4

1 reference

12 September 2017

publication date

29 June 2011

1 reference

Investigational New Drugs

12 September 2017

published in

1 reference

12 September 2017

volume

30

1 reference

12 September 2017

issue

4

1 reference

12 September 2017

page(s)

1389-1395

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-011-9704-7

12 September 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Anti-HIV drugs for cancer therapeutics: back to the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Azidothymidine inhibits melanoma cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Management of recurrent ovarian carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

The DNA damage response: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9704-7

Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis

21 January 2018

1 reference

12 December 2020

Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy.

1 reference

12 December 2020

Pegylated liposomal doxorubicin in ovarian cancer

1 reference

12 December 2020

Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis

1 reference

12 December 2020

10.1007/S10637-011-9704-7

Identifiers

DOI

1 reference

12 September 2017

1 reference